Immunotech Laboratories, Inc. (IMMB)

Market Cap	114.99K +100.0%
Revenue (ttm)	n/a
Net Income	-977.57K
EPS	-0.02
Shares Out	574.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,895
Open	0.0002
Previous Close	n/a
Day's Range	0.0002 - 0.0002
52-Week Range	0.0001 - 0.0002
Beta	-116.27
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Immunotech Laboratories

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as ...

• Industry: Biotechnology
• Sector: Healthcare
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: IMMB

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 19, 2026

Data Sources Report a data error